Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal...

Related Keywords

Texas ,United States ,Stevenc Katz ,Trisalu Trinav ,Sapna Patel ,Twitter ,Exchange Commission ,University Of Texas Md Anderson Cancer Center ,Trisalus Life Sciences ,Nasdaq ,Linkedin ,Society Of Immunotherapy ,Trisalus Life ,Infusion System ,Progression Free Survival ,Disease Control Rate ,Chief Medical Officer ,Pressure Enabled Regional Immuno Oncology ,Pressure Enabled Drug Delivery ,Pancreatic Retrograde Venous Infusion System ,Private Securities Litigation Reform Act ,Markets ,